About Armis Biopharma

We have developed an approach to address the ever-growing threat of drug resistant infections using targeted or localized, as opposed to systemic, administration.  Our approach is to use a targeted or localized administration as opposed to systemic administration. Our approach affords the opportunity to increase the efficacy and lower the toxicity of antimicrobial agents by:

1. Increasing the local concentrations and overcoming drug resistance.
2. Lowering the systemic exposure and, as a result, lowering the toxicity of the drugs.
3. Avoiding the elimination of the natural microbiome in the digestive track of the human body which results in better innate immunity.

The products being developed by Armis will be for the treatment and prevention of severe, localized, drug-resistant infections. We will initially focus on the large and unmet needs in colorectal, orthopedic, cardiothoracic and other surgical indications.